Best Neurology Companies in United Kingdom
The 157 best Neurology companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Markit.
Ranked by disclosed equity funding and recent momentum, the 157 Neurology companies tracked across the United Kingdom have collectively pulled in $3.9B in disclosed capital, with no unicorns yet but a funding base that's clearly building toward something.
The [global neurology market sits at roughly $112.5B in 2025, forecast to reach $180.2B by 2032 at a 6.9% CAGR](https://www.biospace.com/neurology-market-expected-to-witness-sustained-growth), driven by an aging population and accelerating advances in neuroimaging and genetic research. Mission Therapeutics leads the UK directory at $179M raised, with Draig Therapeutics close behind at $140M and Trogenix at $111M. Those figures aren't projections, they're filed capital. So when you look at where the real weight sits, it's concentrated in a handful of companies doing serious translational work. And coverage, I'd note, is flat right now, which means the opportunity cost of missing this cohort is real. Hot themes are cognitive aging studies, post-concussion syndrome, and chronic traumatic encephalopathy, areas where UK-based science has genuine depth. What does it take to break through in a sector this capital-intensive without a unicorn anchor? Probably exactly the kind of focused therapeutic bets Mission Therapeutics and Alchemab, at $83M raised, are already making.
- Neurology Market Expected to Witness Sustained Growth
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in United Kingdom
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Markit Developer of NMDA receptor modulators for neuropsychiatric and neurodevelopmental disorders | $750M | 156 mo ago | Public | 1,030 | — | — | — | — |
| 2 | Spur Therapeutics Developer of gene therapies for debilitating chronic diseases | $401M | 70 mo ago | Acquired | — | Naomi Aoki Founder & Principal | — | 16 patents Engineered stable beta‑glucocerebrosidase enzymes for lysosomal disease therapeutics | — |
| 3 | ReNeuron Group Developer of stem-cell-based therapeutics for stroke disability and critical limb ischemia | $326M | 98 mo ago | Public | 34 | — | — | 152 patents Cell therapy and exosome-based delivery of engineered stem cell-derived microparticles. | — |
| 4 | Mission Therapeutics Developer of small molecule inhibitors targeting specific disease associated enzymes 53Funding top 26%Moat top 26%Patents top 29%Innovation top 35% All 10 signals ▾Fundingtop 26% Moattop 26% Patentstop 29% Innovationtop 35% Talenttop 38% Growthtop 48% Markettop 50% Globalbottom 42% Fin. healthbottom 31% Newsbottom 21% Funding: Raised $179M across 9 rounds · 9 rounds over 15 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 305 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $179M | 8 mo ago | Series D | 45 | Keith Menear Co-Founder | — | 305 patents Small-molecule USP30 deubiquitinase inhibitors for mitochondrial disease, cancer, and fibrosis | — |
| 5 | OMass Therapeutics Developer of therapeutics for immunological and orphan diseases | $166M | 37 mo ago | Series B | 36 36 → 78 (+117%) | Carol Robinson Co-Founder | — | 16 patents Small‑molecule modulators of MC2R, GPR65, and SMO receptors for endocrine and oncology therapies. | 1 job opening |
| 6 | Evox Therapeutics Developer of exosome-based therapeutics for severe neurological and rare diseases | $156M | 64 mo ago | Series C | 73 73 → 40 (-45%) | Samir Andaloussi Co-Founder | — | 193 patents Engineered extracellular vesicle/exosome platforms for targeted delivery of RNA, proteins, and CRISPR tools | — |
| 7 | Beckley Psytech Developer of rapid-acting psychedelic medicines for mental health disorders | $153M | 29 mo ago | Series B | 1 | Cosmo Mellen Co-Founder & CEO | 3 signals ▼40% M&A | 78 patents Formulating and delivering 5‑MeO‑DMT as pharmaceutical/ digital therapies for depression and addiction. | — |
| 8 | Draigtherapeutics Developer of targeted neuromodulators for neuropsychiatric disorders treatment 35Funding top 25%Moat top 35%Talent top 38%Global top 45% All 6 signals ▾Fundingtop 25% Moattop 35% Talenttop 38% Globaltop 45% Techbottom 36% Marketbottom 31% Funding: Raised $140M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Moat: Soonicorn · 5 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 35/100 | $140M | 12 mo ago | Series A | — | Simon Ward Co-Founder | — | — | — |
| 9 | Trogenix Developer of precision cancer treatments using its proprietary gene therapy platform 55Funding top 23%Growth top 28%Talent top 38%Moat top 40% All 7 signals ▾Fundingtop 23% Growthtop 28% Talenttop 38% Moattop 40% Techbottom 47% Globalbottom 45% Marketbottom 35% Funding: Raised $111M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $111M | 8 mo ago | Series A | — | Steve Pollard Co-Founder | — | — | — |
| 10 | COMPASS Pathways Developer of therapies for treating mental disorders | $109M | 34 mo ago | Public | 42 | Lars Wilde Co-Founder | 10 signals ▼23% Earnings · IPO · Leadership | 23 patents Patents concentrated in chemistry & materials | — |
| 11 | Proximagen Small molecules for neurodegenerative disorders, including Parkinson’s and Alzheimers. | $96M | 176 mo ago | Acquired | 28 | Peter Jenner Founder | — | 349 patents Small-molecule SSAO and CXCR4 receptor inhibitors for therapeutic applications | — |
| 12 | Alchemab Developer of antibody therapeutics for treating oncology and neurodegenerative conditions 45Funding top 28%Talent top 28%Moat top 31%Growth top 35% All 7 signals ▾Fundingtop 28% Talenttop 28% Moattop 31% Growthtop 35% Globalbottom 37% Marketbottom 34% Techbottom 33% Funding: Raised $82.7M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $83M | 9 mo ago | Series A | 8 | Jane Osbourn Co-Founder & CEO | — | — | — |
| 13 | AviadoBio Developer of gene therapies for neurodegenerative disorders | $80M | 54 mo ago | Series A | 38 38 → 70 (+84%) | Do Lee Co-Founder | — | 3 patents Antisense nucleic‑acid therapies targeting SOD1 for ALS and CNS drug delivery platforms. | 1 launch · 1 partnership |
| 14 | Pheno Therapeutics Developer of remyelinating therapies for multiple sclerosis | $75M | 51 mo ago | Series A | 2 | Jon Moore CEO | — | — | — |
| 15 | Heptares Develops small molecule drugs targeting GPCRs | $62M | 119 mo ago | Acquired | 168 | Malcolm Weir Co-Founder & CEO | — | — | — |
| 16 | Phagenesis Developer of medical devices for the treatment of Neurogenic dysphagia | $62M | 27 mo ago | Acquired | 22 | Conor Mulrooney Co-Founder & COO | — | 126 patents Bioelectronic therapeutic devices and wearable medical accessories for neuromodulation and dysphagia treatment | — |
| 17 | LoQus23 Developer of oral small molecule therapies to treat neurodegenerative diseases | $61M | 20 mo ago | Series A | 1 | — | — | — | — |
| 18 | AstronauTx Developer of therapeutics for neurodegenerative disorders | $61M | 32 mo ago | Series A | 5 | Ruth Mckernan Co-Founder | — | — | 1 award |
| 19 | WaveBreak Developer of small molecule therapeutics for neurological disorders | $60M | 26 mo ago | Series A | 51 | Bart Henderson CEO | — | — | — |
| 20 | CoMind Provider of a non-invasive brain-computer interface solution for various industries 55Growth top 11%News top 24%Funding top 29%Moat top 42% All 9 signals ▾Growthtop 11% Newstop 24% Fundingtop 29% Moattop 42% Partnerstop 45% Talentbottom 49% Marketbottom 38% Globalbottom 37% Techbottom 36% Growth: Headcount 15 → 36 (+140%) across vintages · Fresh capital in last 24 mo News: 7 BI events in 12 mo (of 7 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $60M | 8 mo ago | Series A | 36 36 → 81 (+125%) | James Dacombe Co-Founder & CEO | 7 signals Funding · Regulatory | — | — |
| 21 | Ixaka Developer of cell-based therapeutic solutions for the treatment of multiple therapeutic conditions | $54M | 65 mo ago | Deadpooled | 9 | Vicente Gonzalez Co-Founder | — | — | — |
| 22 | Levicept Developer of therapeutics for the treatment of chronic pain | $51M | 57 mo ago | Series B | 6 | Simon Westbrook CSO and Founder | — | 105 patents Patents concentrated in chemistry & materials | — |
| 23 | Small Pharma Developer of psychedelic-based therapeutics for mental health conditions | $49M | 63 mo ago | Acquired | 8 | — | — | 148 patents Deuterated psychedelic compounds and specialized delivery formulations for psychiatric therapies | — |
| 24 | C4X Discovery Developer of optimized drug discovery and design services | $43M | 29 mo ago | Public | 46 | — | — | 130 patents Small‑molecule inhibitors of MALT1, NRF2 agonists, and integrin blockers for immuno‑inflammatory therapy | — |
| 25 | Trimtech Therapeutics They develop treatments for CNS and inflammatory disorders | $31M | 15 mo ago | Seed | — | Leo James Co-Founder | — | — | 1 award |
| 26 | Kesmalea Developer of protein homeostasis modulators for therapeutic applications | $30M | 21 mo ago | Series B | 5 | Harry Finch Founder Director | — | — | — |
| 27 | Oxford Endovascular Developer of treatment device for neurovascular disease | $23M | 25 mo ago | Series A | 7 | Andrew Moor Director of R&D | — | 21 patents Self‑expanding intravascular stent tubes and delivery systems for endovascular procedures. | — |
| 28 | NRG Therapeutics Developer of drugs for neurodegenerative diseases | $18M | 9 mo ago | Series B | 5 | Neil Miller Co-Founder and CEO | 4 signals Leadership · Funding | 39 patents Mitochondrial permeability transition pore inhibitors for neuro‑protective therapeutics | — |
| 29 | Neurovalens Developer of non-invasive neurostimulation products | $18M | 10 mo ago | Series A | 22 22 → 29 (+32%) | Anthony Rober Wilcox Executive Director | — | 18 patents Non‑invasive vestibular nerve stimulation devices for anxiety, sleep and post‑COVID therapy | — |
| 30 | Endlyz Developer of small-molecule therapeutics targeting lysosomal dysfunction in neurodegenerative diseases 24Funding top 32%Tech bottom 49%Talent bottom 49%Global bottom 48% All 5 signals ▾Fundingtop 32% Techbottom 49% Talentbottom 49% Globalbottom 48% Marketbottom 25% Funding: Raised $17.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Tech: 13 technologies across 4/8 capability areas · Cloud: Vercel rank vs industry peers · Fliar Intelligence Index 24/100 | $17M | 2 mo ago | Series B | — | Joanna Wolak Co-Founder & CEO | — | — | — |
| 31 | OVM Therapeutic peptide vaccines for cancer | $12M | 19 mo ago | Series B | 5 | Shisong Jiang Founder & Director | — | — | — |
| 32 | Scripta Therapeutics Developer of therapeutics modulating transcription factor activity for disease treatment 27Funding top 36%Talent top 38%Tech bottom 49%Global bottom 45% All 5 signals ▾Fundingtop 36% Talenttop 38% Techbottom 49% Globalbottom 45% Marketbottom 25% Funding: Raised $11.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $12M | 7 mo ago | Seed | — | Jerry Huang Co-Founder & VP Machine Learning | — | — | — |
| 33 | Pangea Botanica Developing and discovering nature-inspired therapeutics | $12M | 37 mo ago | Seed | 8 | Julia Wilde Co-Founder | — | 2 patents Accelerated hardware implementations for high‑speed cosine arithmetic operations | — |
| 34 | Harness Therapeutics Developer of therapeutics for neurological disorders | $11M | 30 mo ago | Series A | 5 | Jan Thirkettle Chief Executive Officer | — | — | — |
| 35 | OKYO Pharma Developer of therapeutics for the treatment of dry eye disease and chronic pain management | $10M | 10 mo ago | Public | 6 | Gary Jacob Chief Executive Officer | 7 signals ▲250% IPO · M&A · Funding | — | 1 expansion |
| 36 | EpilepsyGTx Developer of gene therapies for focal refractory epilepsy 13News top 38%Funding top 40%Partners top 45%Talent bottom 49% All 7 signals ▾Newstop 38% Fundingtop 40% Partnerstop 45% Talentbottom 49% Globalbottom 36% Techbottom 30% Marketbottom 25% News: 3 BI events in 12 mo (of 5 tracked, 1 types) · Top themes: Funding Funding: Raised $10.0M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 13/100 | $10M | 6 mo ago | Series A | — | Nicolas Koebel CEO | 3 signals Funding | — | — |
| 37 | Biodexa Pharmaceuticals Developer of therapeutics for the treatment of brain cancer | $7M | 29 mo ago | Series A | 26 | Stephen Stamp CEO | 17 signals Leadership · IPO · Announcements | — | — |
| 38 | Aurum Biosciences A biopharmaceutical company developing novel oxygen carriers and proprietary software for use with MRI… | $6M | 28 mo ago | Series A | 6 | — | — | 8 patents Assessing and imaging metabolic function using biomedical diagnostic methods | — |
| 39 | Lario Therapeutics Developer of therapeutics for the treatment of neurological disorders | $6M | 22 mo ago | Funding Raised | — | Henning Steinhagen Co-Founder & CEO | — | 25 patents Cav2.3 calcium channel antagonists for neurodegenerative disease therapy | — |
| 40 | AWAKN CRO focused on early stage clinical trial research | $6M | 15 mo ago | Acquired | 3 | — | — | — | — |
| 41 | Neurocentrx Developing products to treat chronic cancer pain. | $5M | 8 mo ago | Seed | 4 | — | — | — | — |
| 42 | Monument Therapeutics Developer of targeted treatments for the treatment of psychiatry and neurological diseases | $5M | 15 mo ago | Seed | 7 | Sheryl Caswell Co-Founder & CDO | — | — | — |
| 43 | QV Bioelectronics Manufacturer of electrotherapy devices for treating brain tumors | $4M | 4 mo ago | Series A | 6 | Christopher Bullock Co-Founder & CTO | — | 25 patents Implantable bioelectronic devices for neural stimulation and monitoring | — |
| 44 | Crucible Therapeutics Developer of RNA-targeting therapies for neurodegenerative diseases | $3M | 12 mo ago | Funding Raised | — | Guillaume Hautbergue Chief Scientific Officer | — | — | — |
| 45 | Solvonis Therapeutics Developer of novel therapeutics for addiction and mental health disorders | $3M | 8 mo ago | Public | — | Anthony Tennyson Co-Founder & Chief Executive Officer | — | — | — |
| 46 | Cerca Provider of a brain scanning medical imaging device for neurological and mental health diagnosis 21Moat top 48%Funding top 49%Talent bottom 49%Tech bottom 48% All 7 signals ▾Moattop 48% Fundingtop 49% Talentbottom 49% Techbottom 48% Fin. healthbottom 42% Globalbottom 32% Marketbottom 28% Moat: Editorial + unicorn rating 5/10 · 6 curated direct competitors tracked Funding: Raised $2.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $3M | 1 mo ago | Series A | 7 | David Woolger Co-Founder & CEO | — | — | 1 job opening · 1 expansion |
| 47 | UpFront Diagnostics Developer of rapid diagnostic tests for stroke detection | $2M | 13 mo ago | Series A | 3 | Edoardo Gaude Co-Founder & Chief Scientific Officer | — | — | 1 award |
| 48 | MYndspan Platform offering detailed reports on cognitive function and brain connectivity | $2M | 14 mo ago | Seed | 5 | Caitlin Baltzer Co-Founder | — | — | — |
| 49 | Reneural Developer of a neurorehabilitation platform integrating virtual reality for stroke recovery | $617K | 19 mo ago | Seed | — | Victor Harabari Founder & CEO | — | — | — |
| 50 | MeOmics Provider of neural biomarker discovery platform for psychiatric disorders | $185K | 4 mo ago | Seed | 6 | Jeremy Hall Co-Founder | — | — | — |
Top 12 Neurology companies in United Kingdom
#1
Series D · Cambridge, England · founded 2011 · 45 employees$178.9Mraised▾
Developer of small molecule inhibitors targeting specific disease associated enzymes. These therapeutic candidates focus on the regulation of cellular quality control processes to address neurodegenerative conditions, heart disease, kidney disease, and fibrosis. The research centers on the modulation of protein degradation pathways to influence disease progression.
- Oct 2025Series D$13.3M
- Jul 2024Grant (prize money)$5.2M
- Mar 2024Series D$32.2M
- Jan 2021Series C$3.7M
#2
Series A · Edinburgh, Scotland · founded 2023$111Mraised▾
Developer of precision cancer treatments using its proprietary gene therapy platform. It leverages proprietary Synthetic Super-Enhancers technology, delivered via Adeno-Associated Virus vectors. It offer therapies for glioblastoma, colorectal cancer, hepatocellular carcinoma, lung squamous cell cancer, and fibrosis.
- Oct 2025Series A$95M
- Aug 2024Series A$11.5M
- Feb 2024Series A$4.4M
#3
Series B · London, England · founded 2021$17.3Mraised▾
Developer of small-molecule therapeutics targeting lysosomal dysfunction in neurodegenerative diseases. The company focuses on developing disease-modifying therapies to restore endo-lysosomal function and reduce neurodegeneration. Their pipeline includes small molecule modulators targeting ATP13A2 and ATP10B lysosomal transporters, both critical for maintaining neuronal health. Initial clinical indications target genetic subsets of Parkinson's disease, with plans to expand into sporadic Parkinson's and other neurodegenerative disorders. The approach aims to address the underlying causes of these diseases rather than just managing symptoms.
- Mar 2026Series B$17.3M
#4
Series A · London, England · founded 2019 · 8 employees$82.7Mraised▾
Developer of antibody therapeutics for treating oncology and neurodegenerative conditions. This organization identifies drug targets by analyzing patient antibody repertoires through deep sequencing and computational analysis. The process focuses on identifying convergent protective antibody responses found in individuals who demonstrate resilience to specific diseases. These findings facilitate the creation of therapeutic candidates intended for clinical application.
- Sep 2025Series A$32M
- Dec 2022Grant (prize money)$2.1M
- 2021Grant (prize money)—
- Apr 2021Series A$82.7M
#5
Series A · London, England · founded 2017 · 36 employees$60Mraised▾
Provider of a non-invasive brain-computer interface solution for various industries. It enables users to develop, design, measure, study, record, process, analyze, manage, and control brain data for decision-making. Its offering includes application development, research, neuroimaging, and stimulation technologies. It caters to the health and manufacturing industries.
- Oct 2025Series A$60M
- 2023Seed—
#6
Series A · Cardiff, Wales · founded 2021$140Mraised▾
Developer of targeted neuromodulators for neuropsychiatric disorders treatment. The company focuses on clinically validated mechanisms underlying prevalent and debilitating neuropsychiatric disorders. It aims to restore synaptic balance and deliver therapeutic benefits for patients. The company is advancing receptor modulators towards clinical development.
- Jun 2025Series A$140M
- 2024Seed—
#7
Series A · England · founded 2020 · 7 employees$2.5Mraised▾
Provider of a brain scanning medical imaging device for neurological and mental health diagnosis. The company has developed a wearable helmet that uses magnetic fields to scan the brain and generate brain functions to diagnose any neurological or psychiatric conditions. The tool provides real-time data for brain networks for cognitive demands for healthcare professionals to aid in the process of treatment and diagnosis.
- Apr 2026Series A$5.1M
- Feb 2024Seed$2.5M
#8
Series A · Waterbeach, Cambridgeshire · founded 2021$10Mraised▾
Developer of gene therapies for focal refractory epilepsy. It offers gene therapy program EPY201 which uses an AAV9 capsid, an engineered Kv1.1 potassium channel and a CAMK2A promoter. It is delivered directly to the target seizure focus by intraparenchymal administration.
- Dec 2025Series A$33M
- Jun 2024Seed$10M
#9
Series A · Belfast, Northern Ireland · founded 2013 · 22 employees$18Mraised▾
Developer of non-invasive neurostimulation products. The company is developing an electronic headset which include Stimu Slim, a small headset-like medical device that targets an area of the brain known to suppress appetite and induces a metabolic shift within the nervous system.
- Aug 2025Series A$8.1M
- Apr 2024Series A$2.7M
- Dec 2021Grant (prize money)$299.4K
- Jul 2020Series A$6.4M
#10
Series B · Cambridge, England · founded 2018 · 5 employees$18.4Mraised▾
Developer of drugs for neurodegenerative diseases.It is involved in developing the small molecule-based drug which can penetrant mitochondrial permeability and transition pore inhibitors to safeguard dopamine cells for neurodegenerative diseases like Parkinson’s disease, Alzheimer’s disease, and motor neuron disease
- Sep 2025Series B$67.5M
- Feb 2023Grant (prize money)$500K
- Nov 2022Series A$18.4M
- May 2022Grant (prize money)$3.4M
#11
Seed · Oxford, England · founded 2025$11.9Mraised▾
Developer of therapeutics modulating transcription factor activity for disease treatment. It focuses on identifying and manipulating master controllers of biology. The company utilizes AI/ML models to reveal novel therapeutics. It validates results in patient-derived models, initially targeting neurodegenerative diseases.
- Nov 2025Seed$11.9M
#12
Series A · Manchester, England · founded 2019 · 6 employees$3.6Mraised▾
Manufacturer of electrotherapy devices for treating brain tumors. The company's flagship product is GRACE, an implanted device that delivers electric field therapy directly to the tumour resection margins where GBM recurrence takes place.
- Jan 2026Grant (prize money)—
- Jan 2026Series A$6.1M
- Apr 2023Grant (prize money)$1.1M
- Jan 2023Seed$2.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in the United Kingdom
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,968 United Kingdom-affiliated papers.
- University College London388
- University of Oxford310
- National Hospital for Neurology and Neurosurgery238
- Imperial College London194
- MRC Brain Network Dynamics Unit185
- Neuromodulation2→23
- Stimulation16→35
- Deep brain stimulation44→59
- Neurostimulation7→22
- Optogenetics1→14
- Neuromodulation19→57
- Neurostimulation37→59
- Brain stimulation15→35
- Vagus nerve stimulation6→22
- Disease13→28
- Neuromodulation14→34
- Neuroprosthetics2→12
- Neurostimulation18→28
- Meta-analysis1→8
- Brain stimulation12→19
Where neurotech is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing neurotech patents in the United Kingdom
United Kingdom neurotech patent filing is accelerating — 134 filings from 71 assignees (2016–2025), led by Galvani Bioelectronics, Bioinduction, UNIV Newcastle; annual filings 5→18.
- Galvani Bioelectronics54
- Bioinduction15
- UNIV Newcastle9
- Imperial College Innovations8
- UNIV Oxford Innovation8
- Goroszeniuk Teodor7
- Smith & Nephew7
- BIOS Health5
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.